Tenax Therapeutics Inc (TENX)
3.549
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
3.66
+0.11
(+3.13%)
After-Hours: 20:00
Tenax Therapeutics Cash from Financing (Quarterly): -0.1745M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.1745M |
| September 30, 2023 | -0.1713M |
| June 30, 2023 | -0.0999M |
| March 31, 2023 | 14.01M |
| December 31, 2022 | 0.0021M |
| September 30, 2022 | -0.0919M |
| June 30, 2022 | 7.792M |
| March 31, 2022 | 0.2288M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 9.193M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.5447M |
| December 31, 2020 | -0.0014M |
| September 30, 2020 | 6.533M |
| June 30, 2020 | 1.935M |
| March 31, 2020 | 2.13M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.0965M |
| December 31, 2018 | 8.907M |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| October 31, 2015 | -0.0484M |
| July 31, 2015 | -0.0518M |
| April 30, 2015 | -0.0511M |
| March 31, 2015 | -0.047M |
| January 31, 2015 | 0.1513M |
| October 31, 2014 | -0.016M |
| July 31, 2014 | 0.1964M |
| April 30, 2014 | 54.99M |
| January 31, 2014 | 6.546M |
| October 31, 2013 | 0.5188M |
| July 31, 2013 | 4.886M |
| April 30, 2013 | 1.437M |
| January 31, 2013 | 0.0915M |
| October 31, 2012 | -0.014M |
| July 31, 2012 | 2.458M |
| April 30, 2012 | 0.0732M |
| January 31, 2012 | 3.597M |
| October 31, 2011 | 0.6106M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1745M
Minimum
Dec 2023
14.01M
Maximum
Mar 2023
2.202M
Average
--
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| CEL-SCI Corp | 6.596M |
| AIM ImmunoTech Inc | 0.147M |
| IGC Pharma Inc | -0.001M |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Protalix BioTherapeutics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.174M |
| Free Cash Flow | -5.904M |
| Free Cash Flow Per Share (Quarterly) | -3.930 |
| Free Cash Flow Yield | -672.2% |